KR870001229A - 7-옥사비시 클로헵탄 치환 디아미드 및 그의 동종 프로스타글란딘 유사체의 제조 방법 - Google Patents

7-옥사비시 클로헵탄 치환 디아미드 및 그의 동종 프로스타글란딘 유사체의 제조 방법 Download PDF

Info

Publication number
KR870001229A
KR870001229A KR1019860005253A KR860005253A KR870001229A KR 870001229 A KR870001229 A KR 870001229A KR 1019860005253 A KR1019860005253 A KR 1019860005253A KR 860005253 A KR860005253 A KR 860005253A KR 870001229 A KR870001229 A KR 870001229A
Authority
KR
South Korea
Prior art keywords
compound
defined above
obtaining
general formula
hydrogen
Prior art date
Application number
KR1019860005253A
Other languages
English (en)
Other versions
KR910004721B1 (ko
Inventor
앤 레이드 죠이스
마사미 나까네
마사미 나까내
Original Assignee
이이. 아르. 스퀴부 앤드 산즈 인코포레이티드
니콜라스 피. 말라레스티니크
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 이이. 아르. 스퀴부 앤드 산즈 인코포레이티드, 니콜라스 피. 말라레스티니크 filed Critical 이이. 아르. 스퀴부 앤드 산즈 인코포레이티드
Publication of KR870001229A publication Critical patent/KR870001229A/ko
Application granted granted Critical
Publication of KR910004721B1 publication Critical patent/KR910004721B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H9/00—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

내용 없음.

Description

7-옥사비시 클로헵탄 치환 디아미드 및 그의 동종 프로스타글란딘 유사체의 제조 방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (6)

  1. 하기 일반식(I)
    [식중, m은 0 내지 4이고, A는 -CH=CH- 또는 -CH2-CH2-이고, n은 1 내지 5이고, Q는 -CH=CH-, -CH2,또는 단일결합이고, R는 CO2H, CO2알킬, CO2알칼리금속, CO2폴리히드록시아민염,또는(여기에서 R4및 R5는 서로 동일하거나 또는 상이한 것으로서, 수소, 저급 알킬, 히드록시, 저급 알콕시기 또는 아릴기이고, R4및 R5중 적어도 1개는 히드록시 및 저급 알콕시기 이외의 기임)이고, p는 1 내지 4이고, R1은 수소 또는 저급 알킬기이고, 9는 1내지 12이고, R2는 수소 또는 저급 알킬기이고, R3은 수소, 저급 알킬, 저급 알케닐, 저급 알키닐, 아릴, 아릴알킬, 저급 알콕시, 아릴알킬옥시, 아릴옥시, 아미노, 알킬아미노, 아릴아미노, (여기에서, n′는 0,1 또는 2임), 알킬아미노알킬, 아릴아미노알킬, 아릴알킬, 아미노알킬,알콕시알킬, 아릴옥시알킬 또는 아릴알콕시알킬기임))으로 표시되는 화합물 및 그의 입체 이성체모두의 제조 방법에 있어서, (A) Q가 CH2또는 단일 결합인 경우, 하기 일반식,
    (식중, m, n, A 및 R1은 상기 정의한 바와 같음)의 화합물을 하기 일반식,
    (식중, q, R2및 R3은 상기 정의한 바와 같음)의 화합물과 반응시켜 하기 일반식,
    (식중, A, n, q, R1, R2및 R3은 상기 정의한 바와 같음)을 갖는 화합물을 얻고,
    (B) Q가 -CH=CH-이고 A가 CH=CH인 경우, 하기 일반식,
    (식중, m, p, q, R1, R2및 R3은 상기 정의한 바와 같음)의 화합물을 하기 일반식,
    (식중, n는 상기 정의한 바와 같다)의 화합물과 반응시켜 하기 일반식,
    (식중, m, n, p, q, R1, R2및 R3은 상기 정의한 바와 같음)의 화합물을 얻고, (C) Q가, 또는이고, A가 CH=CHH인 경우, 하기 일반식,
    (식중, m, p, q, R1, R2및 R3은 상기 정의한 바와 같음)의 화합물을 하기 일반식,
    (여기에서, n는 상기 정의한 바와 같고, x는 1 또는 2임)의 화합물과 반응시켜 하기 일반식,
    (식중, m, n, x, p, q, R1, R2및 R3은 상기 정의한 바와 같음)의 화합물을 얻고, (D) R3이 NH2인 경우, 하기 일반식,
    (식중, m, n, A, Q 및 R1은 상기 정의한 바와 같음)의 화합물을 하기 구조식,
    의 화합물과 반응시키고, 이어서 가수분해시켜서 하기 일반식,
    (식중, m, n, A, Q, R, p, q, R1및 R2는 상기 정의한 바와 같음)의 화합물을 얻고,
    (식중, m, n 및 Q는 상기 정의한 바와 같음)의 화합물을 하기 일반식,
    (식중, q, R2및 R3은 상기 정의한 바와 같음)의 화합물과 반응시켜 하기 일반식,
    (식중, m, n, Q, p, q, R1, R2및 R3은 상기 정의한 바와 같음)의 화합물을 얻고, 이 화합물을 환원시켜서 A가 (CH2)2인 대응하는 화합물을 제조함을 특징으로 하는 방법.
  2. 제1항에 있어서, 제조된 화합물을 LiN(i-C3H7)2와 반응시키고, 이어서 옥소 퍼옥시몰리브데늄(피리딘)-헥사메틸 인산 트리아미드)와 반응시켜서 Q가인 화합물을 얻는 제조 방법.
  3. 제1항에 있어서, 제조된 화합물을 일반식 HNR4R5(여기에서, R4및 R5는 히드록시 또는 알콕시기가 아님)로 표시되는 화합물과 반응시켜 R가인 화합물을 얻는 제조 방법.
  4. 제1항에 있어서, 제조된 화합물(여기에서, R는 CO2알킬기임)을 환원시켜서 R가 CH2H인 화합물을 얻는 제조 방법.
  5. 제1항에 있어서, 제조된 화합물(여기에서, R는 CO2알킬기임)을 가수분해시켜서 R가 CH2OH인 화합물을 얻는 제조 방법.
  6. 제5항에 있어서, 제조된 화합물을 하기 구조식,
    (여기에서, R4는 상기 정의한 바와 같으며, R5′는 수소 또는 알킬기임)의 화합물과 반응시켜 R가,
    인 화합물을 얻는 제조 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019860005253A 1985-07-01 1986-06-30 7-옥사비시클로헵탄 치환 디아미드 및 그의 동종 프로스타글란딘 유사체 KR910004721B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US75094885A 1985-07-01 1985-07-01
US750948 1985-07-01
US853788 1986-04-18
US06/853,788 US4663336A (en) 1985-07-01 1986-04-18 7-oxabicycloheptane substituted diamide and its congener prostaglandin analogs useful in the treatment of thrombotic disease

Publications (2)

Publication Number Publication Date
KR870001229A true KR870001229A (ko) 1987-03-12
KR910004721B1 KR910004721B1 (ko) 1991-07-10

Family

ID=27115346

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019860005253A KR910004721B1 (ko) 1985-07-01 1986-06-30 7-옥사비시클로헵탄 치환 디아미드 및 그의 동종 프로스타글란딘 유사체

Country Status (20)

Country Link
US (1) US4663336A (ko)
EP (1) EP0207684B1 (ko)
JP (1) JPH07103125B2 (ko)
KR (1) KR910004721B1 (ko)
CN (1) CN1009645B (ko)
AT (1) ATE114312T1 (ko)
AU (1) AU603058B2 (ko)
CA (1) CA1284643C (ko)
DE (1) DE3650144T2 (ko)
DK (1) DK162528C (ko)
ES (10) ES8801626A1 (ko)
FI (1) FI93218C (ko)
GR (1) GR861711B (ko)
HU (1) HU196779B (ko)
IE (1) IE65827B1 (ko)
IL (1) IL79210A (ko)
NO (1) NO168038C (ko)
NZ (1) NZ216544A (ko)
PH (1) PH22413A (ko)
PT (1) PT82875B (ko)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1278577C (en) * 1985-11-18 1991-01-02 Tatsuo Tsuri Bicyclic sulfonamide derivatives
US4958036A (en) * 1986-06-04 1990-09-18 E. R. Squibb & Sons, Inc. Enantiomerically selective synthesis of certain N-substituted-2-(carbamyl 7-oxabicyclo[2.2.1]heptane-3-carboxylic acids
US4743697A (en) * 1986-06-04 1988-05-10 E. R. Squibb & Sons, Inc. Process for preparing 7-oxabicycloheptane amino-alcohol intermediates useful in making thromboxane A2 receptor antagonists and novel intermediates procuced therein
US4749715A (en) * 1987-03-02 1988-06-07 E. R. Squibb & Sons, Inc. 7-oxabicycloheptane substituted amino prostaglandin analogs
US4931460A (en) * 1987-09-17 1990-06-05 E. R. Squibb & Sons, Inc. Post-ischemic myocardial dysfunction using thromboxane A2 antagonists
US5066480A (en) * 1988-04-11 1991-11-19 E. R. Squibb & Sons, Inc. Method of preventing or reducing adverse reactions to protamine using a thromboxane a2 receptor antagonist
USH1139H (en) 1988-07-21 1993-02-02 E. R. Squibb & Sons, Inc. Combination of a calcium channel blocker and thromboxane A2 receptor antagonist or synthetase inhibitor and method for treating ischemia employing such combination
US4925873A (en) * 1988-09-01 1990-05-15 E. R. Squibb & Sons, Inc. Method of treating skin injuries using thromboxane A2 receptor antagonists
US4839384A (en) * 1988-10-07 1989-06-13 E. R. Squibb & Sons, Inc. Method of inhibiting onset of or treating migraine headache using a thromboxane A2 receptor antagonist
US4965279A (en) * 1988-11-18 1990-10-23 E. R. Squibb & Sons, Inc. Cyclopropyl aza prostaglandin analogs
US5100889A (en) * 1989-04-03 1992-03-31 E. R. Squibb & Sons, Inc. 7-oxabicycloheptyl substituted heterocyclic amide or ester prostaglandin analogs useful in the treatment of thrombotic and vasospastic disease
US5153327A (en) * 1988-12-23 1992-10-06 E. R. Squibb & Sons, Inc. 7-Oxabicycloheptyl substituted heterocyclic amide or ester prostaglandin analogs useful in the treatment of thrombotic and vasospastic disease
CA2006086A1 (en) * 1989-01-17 1990-07-17 A. K. Gunnar Aberg Method of preventing or treating atherosclerosis using a thromboxane a receptor antagonist
CA2007896A1 (en) * 1989-02-06 1990-08-06 A.K. Gunnar Aberg Method of treating hypertension using a thromboxane a2 receptor antagonist and new combinations
CA2012852A1 (en) * 1989-05-01 1990-11-01 Miguel A. Ondetti Method of inhibiting vasospasm and platelet aggregation resulting from angioplasty using thromboxane a receptor antagonists
US4977174A (en) * 1989-06-12 1990-12-11 E. R. Squibb & Sons, Inc. 7-oxabicycloheptane imidazole prostaglandin analogs useful in the treatment of thrombotic and vasospastic disease
US4975279A (en) * 1989-10-10 1990-12-04 E. R. Squibb & Sons, Inc. Method of improving post-ischemic myocardial function using a thromboxane A2 antagonist in combination with a thrombolytic agent and combination
US5141865A (en) * 1989-11-17 1992-08-25 E. R. Squibb & Sons, Inc. Monoclonal antibodies which bind thromboxane A2 receptor antagonists and diagnostic methods based thereon
US5081266A (en) * 1990-02-26 1992-01-14 E. R. Squibb & Sons, Inc. Process for preparing [1S-[1α,2α(Z),3α,4α]]-7-[3-[[[[(1-oxoheptyl)-amino]acetyl]amino]methyl]-7-oxabicyclo-[2.2.1]hept-2-yl]-5-heptenoic acid
US4978762A (en) * 1990-02-26 1990-12-18 E. R. Squibb & Sons, Inc. Process for preparing [1S-[1α,2α)Z),3α,4α]]-7-[3-[[[[[1-oxoheptyl]-amino]acetyl]amino]methyl]-7-oxabicyclo-[2,2,1]hept-2-yl]-5-heptenoic acid
JP2984077B2 (ja) * 1990-04-19 1999-11-29 塩野義製薬株式会社 スルホニルアミノ置換ビシクロ環系ヒドロキサム酸誘導体
EP0468681B1 (en) * 1990-07-27 1995-05-24 Zeneca Limited Alfa-fluorocarboxylic acid derivatives as intermediates for the preparation of fungicides
US5290799A (en) * 1990-09-19 1994-03-01 E. R. Squibb & Sons, Inc. 7-oxabicycloheptyl substituted heterocyclic thioamide prostaglandin analogs useful in the treatment of thrombotic and vasospastic disease
US5245055A (en) * 1990-12-18 1993-09-14 E. R. Squibb & Sons, Inc. Process for preparing a cis oxabicyclo olefinic acid and ester from an oxabicyclo pyranol
US5084387A (en) * 1990-12-18 1992-01-28 E. R. Squibb & Sons, Inc. Microbiological hydrolysis for the preparation of (exo,exo)-7-oxabicyclo(2.2.1) heptane-2,3, monoacyl ester dimethanol
US5084581A (en) * 1990-12-18 1992-01-28 E. R. Squibb & Sons, Inc. Process for preparing (3R-(3aα,4β,7ββ,7aα))-octahydro-4,7 epoxyisobenzofuranol from associated aldehydes
CA2055572A1 (en) * 1990-12-18 1992-06-19 David Kronenthal Processes and intermediates for thromboxane receptor antagonists
US5266710A (en) * 1990-12-18 1993-11-30 Patel Ramesh N (Exo,exo)-7-oxabicyclo[2.2.1]heptane-2,3-dimethanol; monoacyl ester and diacyl ester
US5126370A (en) * 1990-12-24 1992-06-30 E. R. Squibb & Sons, Inc. Anti-thrombotic heterocyclic amido prostaglandin analogs
US5135939A (en) * 1991-01-28 1992-08-04 E. R. Squibb & Sons, Inc. Heterocyclic ketone prostaglandin analogs
US5158967A (en) * 1991-06-12 1992-10-27 E. R. Squibb & Sons, Inc. 7-oxabicycloheptyl substituted heterocyclic amide prostaglandin analogs useful in the treatment of thrombotic and vasospastic disease
US7312247B2 (en) * 2001-03-27 2007-12-25 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors
US7057057B2 (en) * 2002-05-22 2006-06-06 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors based on alpha-ketoepoxide compounds
US7842727B2 (en) 2001-03-27 2010-11-30 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors
US8026280B2 (en) * 2001-03-27 2011-09-27 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors
DE60234057D1 (de) 2001-07-25 2009-11-26 Raptor Pharmaceutical Inc Zusammensetzungen und verfahren zur modulation des transports durch die blut-hirn-schranke
JP2006508986A (ja) * 2002-11-20 2006-03-16 エルラント ゲネ セラペウチクス エルエルシー ヒストンデアセチラーゼ阻害剤による肺細胞の治療方法
US20060160902A1 (en) * 2004-11-08 2006-07-20 Wiech Norbert L Histone deacetylase inhibitors
EP2392258B1 (en) 2005-04-28 2014-10-08 Proteus Digital Health, Inc. Pharma-informatics system
US8795627B2 (en) 2007-03-21 2014-08-05 Raptor Pharmaceuticals Inc. Treatment of liver disorders by administration of RAP conjugates
AU2010216512B2 (en) 2009-02-20 2016-06-30 2-Bbb Medicines B.V. Glutathione-based drug delivery system
WO2010129819A2 (en) 2009-05-06 2010-11-11 Laboratory Skin Care, Inc. Dermal delivery compositions comprising active agent-calcium phosphate particle complexes and methods of using the same
US20120077778A1 (en) 2010-09-29 2012-03-29 Andrea Bourdelais Ladder-Frame Polyether Conjugates
EP3804717A1 (en) 2014-05-16 2021-04-14 Cumberland Pharmaceuticals, Inc. Compositions and methods of treating systemic sclerosis or pulmonary arterial hypertension
MX2017017155A (es) 2015-06-30 2018-08-09 Cumberland Pharmaceuticals Inc Antagonistas del receptor de tromboxano en erea/asma.
CN115624549A (zh) 2016-05-11 2023-01-20 坎伯兰医药品股份有限公司 用血栓烷-a2受体拮抗剂治疗肌营养不良的组合物和方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4220594A (en) * 1977-11-04 1980-09-02 E. R. Squibb & Sons, Inc. Hexa- and octahydro-4,7-epoxyisobenzofuran-1-ol and hexa- and octahydro-5,8-epoxy-1H-2-benzopyran-3-ol
US4143054A (en) * 1977-11-04 1979-03-06 E. R. Squibb & Sons, Inc. 7-oxabicycloheptane- and 7-oxabicycloheptene compounds
US4187236A (en) * 1977-11-04 1980-02-05 E. R. Squibb & Sons, Inc. 7-Oxabicycloheptane compounds
US4254044A (en) * 1977-11-04 1981-03-03 E. R. Squibb & Sons, Inc. 7-Oxabicycloheptane- and 7-oxabicycloheptene compounds
EP0045118B1 (en) * 1979-01-05 1984-04-04 National Research Development Corporation Intermediates for the synthesis of bicyclo (2,2,1) heptanes and bicyclo (2,2,1) hept-2z-enes
US4228180A (en) * 1979-11-01 1980-10-14 E. R. Squibb & Sons, Inc. 7-Oxabicycloheptane and 7-oxabicycloheptene prostaglandin analogs
ZA829068B (en) * 1980-07-01 1983-02-23 Nat Res Dev Prostaglandins
AU561739B2 (en) * 1981-12-23 1987-05-14 British Technology Group Limited Prostaglandins
KR840003462A (ko) 1982-05-14 1984-09-08 데이빗 핸더슨 복합성분의 가소물질투여 및 혼합총
US4416896A (en) * 1982-05-17 1983-11-22 E. R. Squibb & Sons, Inc. 7-Oxabicyclopheptane substituted amino prostaglandin analogs useful in the treatment of thrombolytic disease
US4456615A (en) 1982-10-25 1984-06-26 E. R. Squibb & Sons, Inc. 7-Oxabicycloheptane substituted amino prostaglandin analogs and their use in inhibiting platelet aggregation and bronchoconstriction
US4456617A (en) * 1983-01-12 1984-06-26 E. R. Squibb & Sons, Inc. 7-Oxabicycloheptane substituted amino prostaglandin analogs and their use in inhibiting platelet aggregation and bronchoconstriction
US4533673A (en) * 1984-01-26 1985-08-06 E. R. Squibb & Sons, Inc. 7-Oxabicycloheptane substituted enaminone prostaglandin analogs and their use in treatment of thrombolytic disease
US4536514A (en) * 1984-04-06 1985-08-20 E. R. Squibb & Sons, Inc. 7-Oxabicycloheptane substituted prostaglandin analogs useful in the treatment of thrombolytic disease
US4654356A (en) * 1985-08-01 1987-03-31 E. R. Squibb & Sons, Inc. 7-oxabicycloheptane substituted diacid diamide prostaglandin analogs

Also Published As

Publication number Publication date
JPS6263589A (ja) 1987-03-20
ES557753A0 (es) 1988-03-16
KR910004721B1 (ko) 1991-07-10
ES8801899A1 (es) 1988-03-01
EP0207684B1 (en) 1994-11-23
CN1009645B (zh) 1990-09-19
US4663336A (en) 1987-05-05
AU603058B2 (en) 1990-11-08
JPH07103125B2 (ja) 1995-11-08
PT82875B (pt) 1988-04-21
CN86105664A (zh) 1987-02-18
ES557752A0 (es) 1988-03-16
ES557748A0 (es) 1988-03-01
PT82875A (en) 1986-07-01
ES8802020A1 (es) 1988-03-16
ES557750A0 (es) 1988-03-01
ATE114312T1 (de) 1994-12-15
IL79210A (en) 1991-03-10
ES8802017A1 (es) 1988-03-16
ES8900229A1 (es) 1989-04-01
IE861749L (en) 1987-01-01
HUT45041A (en) 1988-05-30
IE65827B1 (en) 1995-11-15
PH22413A (en) 1988-08-26
DE3650144D1 (de) 1995-01-05
NO168038C (no) 1992-01-08
DK162528B (da) 1991-11-11
NO862635L (no) 1987-01-02
FI93218B (fi) 1994-11-30
ES556530A0 (es) 1988-02-16
GR861711B (en) 1986-11-03
NZ216544A (en) 1990-02-26
IL79210A0 (en) 1986-09-30
ES8802016A1 (es) 1988-03-16
ES8801626A1 (es) 1988-02-16
EP0207684A3 (en) 1987-04-29
FI862797A (fi) 1987-01-02
NO862635D0 (no) 1986-06-30
FI93218C (fi) 1995-03-10
ES557746A0 (es) 1988-03-16
DK310686A (da) 1987-01-02
ES557747A0 (es) 1988-03-16
FI862797A0 (fi) 1986-07-01
ES557749A0 (es) 1989-04-01
ES557754A0 (es) 1987-12-01
HU196779B (en) 1989-01-30
ES8801898A1 (es) 1988-03-01
AU5871586A (en) 1987-01-08
NO168038B (no) 1991-09-30
ES8802018A1 (es) 1988-03-16
DK310686D0 (da) 1986-06-30
ES8802019A1 (es) 1988-03-16
DE3650144T2 (de) 1995-04-06
CA1284643C (en) 1991-06-04
ES8800896A1 (es) 1987-12-01
ES557751A0 (es) 1988-03-16
EP0207684A2 (en) 1987-01-07
DK162528C (da) 1992-03-30

Similar Documents

Publication Publication Date Title
KR870001229A (ko) 7-옥사비시 클로헵탄 치환 디아미드 및 그의 동종 프로스타글란딘 유사체의 제조 방법
CA1238910A (en) CARBOXYALKENOIC ACIDS
FR2368488A1 (fr) Procede pour la preparation de methoxypsoralene
DE69515770D1 (de) Verfahren zur Produktion von Thiophospholipiden des Aether-Typs
ES8200092A1 (es) Procedimiento para la sintesis de esteres de la n-(4'hidro- xifenil) acetamida con acidos 5-benzoil-1-metilpirrol-2-ace-tico
PT71432A (en) Clavulanic acid derivatives a process for their preparation and their use
TH2899EX (th) กรรมวิธีในการเตรียมอนุพันธ์ของกรดควิโนลีนคาร์บอกซิลิค

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 19970701

Year of fee payment: 7

LAPS Lapse due to unpaid annual fee